Mendelian Randomization Studies in Atherosclerotic Cardiovascular Diseases

키워드

참고문헌 (69)

1. Benjamin EJ, "Heart disease and stroke statistics-2019 update : a report from the American Heart Association", Circulation, 139, pp.e56~ (2019)
2. Roth GA, "Global burden of cardiovascular diseases and risk factors, 1990-2019 : update from the GBD 2019 Study", J Am Coll Cardiol, 76, pp.2982~3021 (2020)
3. Libby P, "Atherosclerosis", Nat Rev Dis Primers, 5, pp.56~ (2019)
4. Kronzon I, "Aortic atherosclerotic disease and stroke", Circulation, 114, pp.63~75 (2006)
5. Libby P, "Inflammation and atherosclerosis", Circulation, 105, pp.1135~1143 (2002)
6. Valanti EK, "Advances in biological therapies for dyslipidemias and atherosclerosis", Metabolism, 116, pp.154461~ (2021)
7. Cuzick J, "The importance of long-term follow up of participants in clinical trials", Br J Cancer, 128, pp.432~438 (2023)
8. Meuli L, "Understanding confounding in observational studies", Eur J Vasc Endovasc Surg, 55, pp.737~ (2018)
9. Hwang TJ, "Failure of investigational drugs in late-stage clinical development and publication of trial results", JAMA Intern Med, 176, pp.1826~1833 (2016)
10. FitzGerald GA, "Testing cardiovascular drug safety and efficacy in randomized trials", Circ Res, 114, pp.1156~1161 (2014)
11. Swanson SA, "Nature as a trialist? : deconstructing the analogy between Mendelian randomization and randomized trials", Epidemiology, 28, pp.653~659 (2017)
12. Goldstein CE, "Ethical issues in pragmatic randomized controlled trials : a review of the recent literature identifies gaps in ethical argumentation", BMC Med Ethics, 19, pp.14~ (2018)
13. Niewada M, "Lifestyle modification for stroke prevention : facts and fiction", Curr Opin Neurol, 29, pp.9~13 (2016)
14. McEvoy RD, "Randomized clinical trials of cardiovascular disease in obstructive sleep apnea: understanding and overcoming bias", Sleep (Basel), 44, pp.zsab019~ (2021)
15. Davey Smith G, "Mendelian randomization : genetic anchors for causal inference in epidemiological studies", Hum Mol Genet, 23, pp.R89~ (2014)
16. Davey Smith G, "Mendel’s laws, Mendelian randomization and causal inference in observational data : substantive and nomenclatural issues", Eur J Epidemiol, 35, pp.99~111 (2020)
17. Sattar N, "Reverse causality in cardiovascular epidemiological research : more common than imagined?", Circulation, 135, pp.2369~2372 (2017)
18. Arsenault BJ, "From the garden to the clinic : how Mendelian randomization is shaping up atherosclerotic cardiovascular disease prevention strategies", Eur Heart J, 43, pp.4447~4449 (2022)
19. Richmond RC, "Mendelian randomization : concepts and scope", Cold Spring Harb Perspect Med, 12, pp.a040501~ (2022)
20. Greenland S, "An introduction to instrumental variables for epidemiologists", Int J Epidemiol, 47, pp.358~ (2018)
21. Martens EP, "Instrumental variables : application and limitations", Epidemiology, 17, pp.260~267 (2006)
22. Mortensen MB, "Low-density lipoprotein cholesterol is predominantly associated with atherosclerotic cardiovascular disease events in patients with evidence of coronary atherosclerosis : the Western Denmark Heart Registry", Circulation, 147, pp.1053~1063 (2023)
23. Ference BA, "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel", Eur Heart J, 38, pp.2459~2472 (2017)
24. Ference BA, "Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes", N Engl J Med, 375, pp.2144~2153 (2016)
25. Sabatine MS, "Efficacy and safety of evolocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1500~1509 (2015)
26. Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
27. Kosoglou T, "Ezetimibe : a review of its metabolism, pharmacokinetics and drug interactions", Clin Pharmacokinet, 44, pp.467~494 (2005)
28. Holmes MV, "Mendelian randomization of blood lipids for coronary heart disease", Eur Heart J, 36, pp.539~550 (2015)
29. Cannon CP, "Safety of anacetrapib in patients with or at high risk for coronary heart disease", N Engl J Med, 363, pp.2406~2415 (2010)
30. ACCORD Study Group, "Effects of combination lipid therapy in type 2 diabetes mellitus", N Engl J Med, 362, pp.1563~1574 (2010)
31. Shah S, "Causal relevance of blood lipid fractions in the development of carotid atherosclerosis : Mendelian randomization analysis", Circ Cardiovasc Genet, 6, pp.63~72 (2013)
32. Do R, "Common variants associated with plasma triglycerides and risk for coronary artery disease", Nat Genet, 45, pp.1345~1352 (2013)
33. Maranhão RC, "Lipoprotein(a) : structure, pathophysiology and clinical implications", Arq Bras Cardiol, 103, pp.76~84 (2014)
34. Tsimikas S, "Emerging RNA therapeutics to lower blood levels of Lp(a) : JACC Focus Seminar 2", 4, 2021, pp.77, 1576~1589
35. Li C, "The correlation between lipoprotein(a)and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg", dL, 2021, pp.21, 41~
36. Wang S, "The relationship between lipoprotein(a)and risk of cardiovascular disease : a Mendelian randomization analysis", Eur J Med Res, 27, pp.211~ (2022)
37. Sampson UK, "Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins : the evidence, etiology, and therapeutic challenges", Curr Atheroscler Rep, 14, pp.1~10 (2012)
38. Navarese EP, "Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering : a systematic review and meta-analysis", JAMA, 319, pp.1566~1579 (2018)
39. Navarese EP, "Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes : a Mendelian randomization study", Arterioscler Thromb Vasc Biol, 43, pp.e373~ (2023)
40. Pepys MB, "C-reactive protein : a critical update", J Clin Invest, 111, pp.1805~1812 (2003)
41. Emerging Risk Factors Collaboration, "C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality : an individual participant meta-analysis", Lancet, 375, pp.132~140 (2010)
42. Zhang YX, "Coronary C-reactive protein distribution : its relation to development of atherosclerosis", Atherosclerosis, 145, pp.375~379 (1999)
43. C Reactive Protein Coronary Heart Disease Genetics Collaboration(CCGC), "Association between C reactive protein and coronary heart disease : Mendelian randomisation analysis based on individual participant data", BMJ, 342, pp.d548~ (2011)
44. Ridker PM, "Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men", Circulation, 101, pp.1767~1772 (2000)
45. Danesh J, "Long-term interleukin-6 levels and subsequent risk of coronary heart disease : two new prospective studies and a systematic review", PLoS Med, 5, pp.e78~ (2008)
46. Sattar N, "Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?", PLoS Med, 6, pp.e1000099~ (2009)
47. Smith GD, "‘Mendelian randomization’ : can genetic epidemiology contribute to understanding environmental determinants of disease?", Int J Epidemiol, 32, pp.1~22 (2003)
48. Burgess S, "Avoiding bias from weak instruments in Mendelian randomization studies", Int J Epidemiol, 40, pp.755~764 (2011)
49. Levin MG, "Genetics of smoking and risk of atherosclerotic cardiovascular diseases : a Mendelian randomization study", JAMA Netw Open, 4, pp.e2034461~ (2021)
50. Pierce BL, "The effect of non-differential measurement error on bias, precision and power in Mendelian randomization studies", Int J Epidemiol, 41, pp.1383~1393 (2012)
51. Burgess S, "Mendelian randomization with a binary exposure variable : interpretation and presentation of causal estimates", Eur J Epidemiol, 33, pp.947~952 (2018)
52. Bowden J, "Mendelian randomization with invalid instruments : effect estimation and bias detection through Egger regression", Int J Epidemiol, 44, pp.512~525 (2015)
53. Price AL, "Principal components analysis corrects for stratification in genome-wide association studies", Nat Genet, 38, pp.904~909 (2006)
54. Sudlow C, "UK biobank : an open access resource for identifying the causes of a wide range of complex diseases of middle and old age", PLoS Med, 12, pp.e1001779~ (2015)
55. Hemani G, "The MR-base platform supports systematic causal inference across the human phenome", eLife, 7, pp.e34408~ (2018)
56. Relton CL, "Two-step epigenetic Mendelian randomization : a strategy for establishing the causal role of epigenetic processes in pathways to disease", Int J Epidemiol, 41, pp.161~176 (2012)
57. Holmes MV, "Mendelian randomization in cardiometabolic disease : challenges in evaluating causality", Nat Rev Cardiol, 14, pp.577~590 (2017)
58. Palmer TM, "Using multiple genetic variants as instrumental variables for modifiable risk factors", Stat Methods Med Res, 21, pp.223~242 (2012)
59. Burgess S, "Mendelian randomization analysis with multiple genetic variants using summarized data", Genet Epidemiol, 37, pp.658~665 (2013)
60. Inouye M, "Genomic risk prediction of coronary artery disease in 480, 000 adults : implications for primary prevention", J Am Coll Cardiol, 72, pp.1883~1893 (2018)
61. Barabási AL, "Network medicine : a network-based approach to human disease", Nat Rev Genet, 12, pp.56~68 (2011)
62. MacArthur J, "The new NHGRI-EBI Catalog of published genome-wide association studies(GWAS Catalog)", Nucleic Acids Res, 45, pp.D896~D901 (2017)
63. Walker VM, "Mendelian randomization : a novel approach for the prediction of adverse drug events and drug repurposing opportunities", Int J Epidemiol, 46, pp.2078~2089 (2017)
64. Shabani M, "Rules for processing genetic data for research purposes in view of the new EU General Data Protection Regulation", Eur J Hum Genet, 26, pp.149~156 (2018)
65. Global Alliance for Genomics and Health, "GENOMICS. A federated ecosystem for sharing genomic, clinical data", Science, 352, pp.1278~1280 (2016)
66. Khera AV, "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations", Nat Genet, 50, pp.1219~1224 (2018)
67. Athieniti E, "A guide to multi-omics data collection and integration for translational medicine", Comput Struct Biotechnol J, 21, pp.134~149 (2022)
68. Malina S, "Deep Mendelian randomization : Investigating the causal knowledge of genomic deep learning models", PLOS Comput Biol, 18, pp.e1009880~ (2022)
69. Leong A, "Cardiometabolic risk factors for COVID-19 susceptibility and severity : a Mendelian randomization analysis", PLoS Med, 18, pp.e1003553~ (2021)

관련 논문AI추천